J
John Curran
Researcher at Foundation Medicine
Publications - 14
Citations - 3163
John Curran is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 8, co-authored 13 publications receiving 2742 citations.
Papers
More filters
Journal ArticleDOI
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton,Alex Fichtenholtz,Geoff Otto,Kai Wang,Sean R. Downing,Jie He,Michael Schnall-Levin,Jared White,Eric M. Sanford,Peter An,James Sun,Frank Juhn,Kristina W. Brennan,Kiel Iwanik,Ashley Maillet,Jamie Buell,Emily White,Mandy Zhao,Sohail Balasubramanian,Selmira Terzic,Tina Richards,Vera Banning,Lazaro Garcia,Kristen Mahoney,Zac Zwirko,Amy Donahue,Himisha Beltran,Himisha Beltran,Juan Miguel Mosquera,Juan Miguel Mosquera,Mark A. Rubin,Mark A. Rubin,Snjezana Dogan,Cyrus V. Hedvat,Michael F. Berger,Lajos Pusztai,Matthias Lechner,Chris Boshoff,Mirna Jarosz,Christine Vietz,Alexander N. Parker,Vincent A. Miller,Jeffrey S. Ross,Jeffrey S. Ross,John Curran,Maureen T. Cronin,Philip J. Stephens,Doron Lipson,Roman Yelensky +48 more
TL;DR: A test based on massively parallel DNA sequencing to characterize base substitutions, short insertions and deletions (indels), copy number alterations and selected fusions across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded (FFPE) clinical specimens is described.
Journal ArticleDOI
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson,Marzia Capelletti,Roman Yelensky,Geoff Otto,Alexander N. Parker,Mirna Jarosz,John Curran,Sohail Balasubramanian,Troy Bloom,Kristina W. Brennan,Amy Donahue,Sean R. Downing,Garrett M. Frampton,Lazaro Garcia,Frank Juhn,Kathy C Mitchell,Emily White,Jared White,Zac Zwirko,Tamar Peretz,Hovav Nechushtan,Lior Soussan-Gutman,Jhingook Kim,Hidefumi Sasaki,Hyeong Ryul Kim,Seung-Il Park,Dalia Ercan,Christine E. Sheehan,Jeffrey S. Ross,Jeffrey S. Ross,Maureen T. Cronin,Pasi A. Jänne,Philip J. Stephens +32 more
TL;DR: Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non–small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorective cancer sample and KIF5B-RET in a lung adenocarcinoma.
Journal ArticleDOI
Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency.
Emanuela Castigli,Stephen A. Wilson,Lilit Garibyan,Rima Rachid,Francisco A. Bonilla,Lynda C. Schneider,Massimo Morra,John Curran,Raif S. Geha +8 more
TL;DR: Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency and the importance of knowing the carrier and removal status of these variants in the immune system is investigated.
Journal ArticleDOI
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy
Jeffrey S. Ross,Jeffrey S. Ross,Kai Wang,Rami N. Al-Rohil,Tipu Nazeer,Christine E. Sheehan,Geoff Otto,Jie He,Gary A. Palmer,Roman Yelensky,Doron Lipson,Siraj M. Ali,Sohail Balasubramanian,John Curran,Lazlo Garcia,Kristen Mahoney,Sean R. Downing,Matthew J. Hawryluk,Vincent A. Miller,Philip J. Stephens +19 more
TL;DR: Comprehensive NGS of 35 UCs of the bladder revealed a diverse spectrum of actionable GAs in 83% of cases, which has the potential to inform treatment decisions for patients with relapsed and metastatic disease.
Journal ArticleDOI
Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations
Jeffrey S. Ross,Kai Wang,Christine E. Sheehan,Ann B. Boguniewicz,Geoff Otto,Sean R. Downing,James Sun,Jie He,John Curran,Siraj M. Ali,Roman Yelensky,Doron Lipson,Gary A. Palmer,Vincent A. Miller,Philip J. Stephens +14 more
TL;DR: Comprehensive genomic profiling of relapsed CDH1-mutated ILC revealed actionable genomic alterations in 86% of cases, featured a high incidence of ERBB2 alterations, and can reveal actionable alterations that can inform treatment decisions for patients with ILC.